Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.51 |
| ▸ | DRD3 | P35462 | 7/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11943373 | 0.90 | SMN1; SMN2 (0.50) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943363 | 0.88 | DRD4 (0.48) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943334 | 0.84 | DRD4 (0.52) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943344 | 0.82 | SMN1; SMN2 (0.42) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943340 | 0.82 | ALDH1A1 (0.42) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943368 | 0.81 | ALDH1A1 (0.43) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943397 | 0.81 | BCL2L1 (0.48) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943360 | 0.80 | ALDH1A1 (0.53) | DRD4DRD3DRD2SMN1; SMN2POLB | |
| SCHEMBL11943341 | 0.80 | SIGMAR1 (0.48) | SMN1; SMN2POLBMAPTALDH1A1LMNA | |
| SCHEMBL11943353 | 0.80 | SMN1; SMN2 (0.48) | DRD4DRD3DRD2SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | DRD4 4875/4885DRD3 4829/4885DRD2 4876/4885 |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | DPM1, GMPS, MAN2A1 | DRD4 4876/4885DRD3 4865/4885DRD2 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.